Drug Profile
Osteopoietin
Latest Information Update: 07 Sep 1998
Price :
$50
*
At a glance
- Originator Metra Biosystems
- Class Glycoproteins; Osteoporosis therapies
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 16 Oct 1996 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)